Tafasitamab-cxix

What Istafasitamab-cxix?

• Tafasitamab-cxix (Monjuvi) is a CD19-directed cytolytic antibody given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

What are the uses of this medicine?

• Tafasitamab-cxix (Monjuvi) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

How does this medicine work?

• Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).
• Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Who Should Not Use this medicine ?

• This medicine have no usage limitations

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• Administer premedications 30 minutes to 2 hours prior to starting Monjuvi infusion to minimize infusion-related reactions.
• Premedications may include acetaminophen, histamine H1 receptor antagonists, histamine H2 receptor antagonists, and/or glucocorticosteroids.
• For patients not experiencing infusion-related reactions during the first 3 infusions, premedication is optional for subsequent infusions.
• If a patient experiences an infusion-related reaction, administer premedications before each subsequent infusion.

The recommended dosage of Monjuvi is 12 mg/kg as an intravenous infusion according to the following dosing schedule:

• Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle.
• Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle.
• Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.

• Administer Monjuvi in combination with lenalidomide for a maximum of 12 cycles and then continue Monjuvi as monotherapy until disease progression or unacceptable toxicity.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As injection: 200 mg of tafasitamab-cxix as lyophilized powder in single-dose vial for reconstitution.

This medicine is available in fallowing brand namesː

• Monjuvi

What side effects can this medication cause?

Common possible side effects of this medicine include:

• neutropenia
• fatigue
• anemia
• diarrhea
• thrombocytopenia
• cough
• pyrexia
• peripheral edema
• respiratory tract infection
• decreased appetite

Monjuvi may cause serious side effects, including:

• Infusion reactions
• Low blood cell counts
• Infections

What special precautions should I follow?

• Monitor patients frequently during infusion. Interrupt or discontinue if infusion-related reactions occurs.
• Monjuvi may cause Myelosuppression. Monitor complete blood counts. Manage using dose modifications and growth factor support. Interrupt or discontinue Monjuvi based on severity.
• Bacterial, fungal and viral infections can occur during and following Monjuvi. Monitor patients for infections.
• Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• There are no available data on Monjuvi use in pregnant women to evaluate for a drug-associated risk.
• Based on its mechanism of action, Monjuvi may cause fetal B-cell depletion when administered to a pregnant woman.

Can this medicine be used in children?

• The safety and effectiveness of Monjuvi in pediatric patients have not been established.

What should I know about storage and disposal of this medication?

• Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not shake. Do not freeze.

Tafasitamab-cxix Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

• Dailymed label info on Tafasitamab-cxix
• FDA Tafasitamab-cxix

Tafasitamab-cxix Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Resources

Frequently asked questions

‎